Business & Finance

Advancis Pharmaceutical provides update on Keflex launch, finances

Published in Drug Law Weekly, November 14th, 2006

Advancis Pharmaceutical Corp. (AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, provided an update on the launch of its recently approved 750mg strength Keflex Capsules (Cephalexin, USP) and revised its financial expectations for the remainder of 2006.

Retail pharmacy stocking of Keflex 750 was lower than expected in August and September of 2006, and, as a result, the company has reissued financial guidance for 2006. In late September, Advancis commenced specific initiatives to significantly increase the number of pharmacies stocking Keflex 750. Based on these initiatives, the company believes more than 20,000...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2006-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry